TrialHeart and vessels2020

Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.

Junichiro Shimamatsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.